Sirolimus-eluting stents for treatment of drug-eluting versus bare-metal stents restenosis: 42-month clinical outcomes from a Chinese single Center

Chinese Medical Journal

Volumn 125, Issue 19, 2012, Pages 3398-3403

  Yan, Rong qiang ^a   Chen, Ji lin ^a   Gao, Li jian ^a   Yang, Yue jin ^a   Li, Jian jun ^a   Qiao, Shu bin ^a   Xu, Bo ^a   Yao, Min ^a   Qin, Xue wen ^a   Liu, Hai bo ^a   Wu, Yong jian ^a   Yuan, Jin qing ^a   Chen, Jue ^a   You, Shi jie ^a   Dai, Jun ^a   Gao, Run lin ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Drug eluting stents; Percutaneous coronary intervention; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; BRAIN ISCHEMIA; DEATH; DEVICE SAFETY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RESTENOSIS; RETROSPECTIVE STUDY; REVASCULARIZATION; SMOKING; STENT THROMBOSIS; TREATMENT OUTCOME; VASCULAR DISEASE;

AGED; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; SIROLIMUS; STENTS;

EID: 84867426871     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.19.007     Document Type: Article

References (24)

1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
2. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
3. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370: 937-948.
4. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. ESIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362: 1093-1099.
5. Schampaert E, Cohen EA, Schlüter M, Reeves F, Traboulsi M, Title LM, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004; 43: 1110-1115.
6. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: 480-486.
7. Tagliareni F, La Manna A, Saia F, Marzocchi A, Tamburino C. Long-term clinical follow-up of drug-eluting stent restenosis treatment: retrospective analysis from two high volume catheterization laboratories. EuroIntervention 2010; 5: 703-708.
8. Kitahara H, Kobayashi Y, Takebayashi H, Fujimoto Y, Nakamura Y, Kuroda N, et al. Re-restenosis and target lesion revascularization after treatment of sirolimus-eluting stent restenosis: retrospective analysis of 4 Japanese hospitals. Circ J 2009; 73: 867-871.
9. Dibra A, Kastrati A, Alfonso F, Seyfarth M, Pérez-Vizcayno MJ, Mehilli J, et al. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: Meta-analysis of randomized trials. J Am Coll Cardiol 2007; 49: 616-623.
10. Liistro F, Fineschi M, Angioli P, Sinicropi G, Faisini G, Gori T, et al. Effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis: The TRUE (Tuscany registry of sirolimus for unselected in-stent restenosis) registry. J Am Coll Cardiol 2006; 48: 270-275.
11. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, et al. Sirolimus-eluting stent or paclitaxel-eluting stent versus balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005; 293: 165-171.
12. Stone GW, Ellis SG, O'Shaughnessy CD, Martin SL, Satler L, McGarry T, et al. Paclitaxel-eluting stents versus vascular brachytherapy for instent restenosis within bare-metal stents. The TAXUS V ISR randomized trial. JAMA 2006; 295: 1253-1263.
13. Nishihira K, Shibata K, Ishikawa T, Nomura K, Nakama T, Mine D, et al. Repeated sirolimus-eluting stent implantation to treat sirolimus-eluting stent and bare-metal stent restenosis. Circ J 2010; 74: 2329-2333.
14. Steinberg DH, Gaglia MA Jr, Pinto Slottow TL, Roy P, Bonello L, De Labriolle A, et al. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents. Am J Cardiol 2009; 103: 491-495.
15. Whan Lee C, Kim SH, Suh J, Park DW, Lee SH, Kim YH, et al. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents. Catheter Cardiovasc Interv 2008; 71: 594-598.
16. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999; 100: 1872-1878.
17. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351.
18. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs. balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005; 293: 165-171.
19. Alfonso F, Pérez-Vizcayno MJ, Hernandez R, Fernandez C, Escaned J, Banuelos C, et al. Sirolimus-eluting stents versus bare-metal stents in patients with in-stent restenosis: results of a pooled analysis of two randomized studies. Catheter Cardiovasc Interv 2008; 72: 459-467.
20. Holmes DR Jr, Teirstein P, Satler L, Skeler L, Sketch M, O'Malley J, et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA 2006; 295: 1264-1273.
21. Abizaid A, Costa R, Banning A, Bratorelli AL, Dzavik V, Ellis S, et al. The sirolimus-eluting Cypher select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: insights from the e-SELECT (Multicenter Post-Market Surveillance) Registry. J Am Coll Cardiol Intv 2012; 5: 64-71.
22. Aminian A, Kabir T, Eeckhout E. Treatment of drug-eluting stent restenosis: an emerging challenge. Catheter Cardiovasc Interv 2009; 74: 108-116.
23. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005; 112: 270-278.
24. Lim SY, Jeong MH, Hong SJ, Lim do S, Moon JY, Hong YJ, et al. Inflammation and delayed endothelization with overlapping drug eluting stents in a porcine model of in-stent restenosis. Circ J 2008; 72: 463-468.